Overview

Toxicity Substudy of Evaluation of Subcutaneous Proleukin in a Randomised International Trial (ESPRIT): TOXIL-2 Substudy

Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This substudy is an open-label, randomised study comparing the uptake of recombinant interleukin-2 (rIL-2) in HIV-1 infected individuals receiving different combinations of antiemetics and analgesic agents during rIL-2 dosing in ESPRIT. The design is a factorial one with 4 arms. All patients will receive regular ibuprofen and paracetamol from days 1-6 of the rIL-2 dosing cycle; in addition, patients will be randomised to receive one of two antiemetic combinations, i.e. ondansetron or metoclopramide with or without low dose codeine phosphate as an additional analgesic agent.
Phase:
Phase 3
Details
Lead Sponsor:
Kirby Institute
Collaborator:
The University of New South Wales
Treatments:
Acetaminophen
Codeine
Ibuprofen
Metoclopramide
Ondansetron